See more : International Bancshares Corporation (IBOC) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Diffusion Engineers Limited (DIFFNKG.BO) Income Statement Analysis – Financial Results
- TM (1480.TWO) Income Statement Analysis – Financial Results
- NewBridge Global Ventures, Inc. (NBGV) Income Statement Analysis – Financial Results
- QYOU Media Inc. (QYOUF) Income Statement Analysis – Financial Results
- Syntonic Limited (SYT.AX) Income Statement Analysis – Financial Results
Invitae Corporation (NVTA)
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M | 8.38M | 1.60M | 148.00K | 0.00 |
| Cost of Revenue | 417.26M | 348.67M | 198.28M | 118.10M | 80.11M | 50.14M | 27.88M | 16.52M | 5.62M | 667.00K | 0.00 |
| Gross Profit | 99.05M | 111.78M | 81.32M | 98.72M | 67.59M | 18.08M | -2.83M | -8.15M | -4.02M | -519.00K | 0.00 |
| Gross Profit Ratio | 19.18% | 24.28% | 29.09% | 45.53% | 45.76% | 26.50% | -11.30% | -97.22% | -250.62% | -350.68% | 0.00% |
| Research & Development | 402.09M | 416.09M | 240.61M | 141.53M | 63.50M | 46.47M | 44.63M | 42.81M | 22.14M | 16.04M | 5.56M |
| General & Administrative | 192.31M | 248.07M | 324.57M | 79.07M | 52.23M | 39.47M | 24.09M | 16.05M | 12.61M | 5.76M | 3.00M |
| Selling & Marketing | 218.88M | 225.91M | 168.32M | 122.24M | 74.43M | 53.42M | 28.64M | 22.48M | 8.76M | 2.43M | 0.00 |
| SG&A | 411.20M | 473.98M | 492.89M | 201.31M | 126.66M | 92.89M | 52.72M | 38.53M | 21.37M | 8.20M | 3.00M |
| Other Expenses | 8.05M | 25.68M | -32.33M | -3.89M | -2.57M | -303.00K | 348.00K | -94.00K | -79.00K | -26.00K | 2.00K |
| Operating Expenses | 813.28M | 890.07M | 733.50M | 342.83M | 190.15M | 139.36M | 97.35M | 81.33M | 43.51M | 24.23M | 8.56M |
| Cost & Expenses | 1.23B | 1.24B | 931.77M | 460.94M | 270.26M | 189.50M | 125.23M | 97.86M | 49.13M | 24.90M | 8.56M |
| Interest Income | 56.75M | 49.90M | 29.77M | 12.41M | 0.00 | 0.00 | 0.00 | 211.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K | 0.00 | 61.00K | 59.00K | 43.00K |
| Depreciation & Amortization | 150.13M | 106.15M | 6.72M | 12.32M | 13.54M | 9.18M | 6.55M | 5.32M | 2.32M | 928.00K | 277.00K |
| EBITDA | -3.12B | -391.64M | -652.17M | -244.11M | -111.59M | -121.58M | -93.63M | -89.48M | -45.19M | -23.85M | -8.28M |
| EBITDA Ratio | -109.26% | -145.97% | -230.85% | -106.91% | -75.55% | -178.22% | -398.57% | -1,068.00% | -2,968.02% | -16,115.54% | 0.00% |
| Operating Income | -714.24M | -778.29M | -652.17M | -244.11M | -122.56M | -121.28M | -100.18M | -89.48M | -47.53M | -24.75M | -8.56M |
| Operating Income Ratio | -138.34% | -169.03% | -233.25% | -112.59% | -82.98% | -177.77% | -399.96% | -1,068.00% | -2,963.09% | -16,725.00% | 0.00% |
| Total Other Income/Expenses | -2.44B | 362.42M | -62.10M | -16.30M | -9.60M | -3.96M | -73.00K | -305.00K | 36.00K | -85.00K | -41.00K |
| Income Before Tax | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Income Before Tax Ratio | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| Income Tax Expense | -44.90M | -36.86M | -105.40M | -18.45M | -2.80M | -1.86M | -5.78M | -5.11M | -2.33M | 33.00K | 45.00K |
| Net Income | -3.11B | -379.01M | -608.87M | -241.97M | -129.36M | -123.38M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Net Income Ratio | -601.64% | -82.31% | -217.77% | -111.60% | -87.58% | -180.85% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| EPS | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| EPS Diluted | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| Weighted Avg Shares Out | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
| Weighted Avg Shares Out (Dil) | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
Why Invitae Stock Is Crashing Today
Invitae announced an agreement to exchange old notes for new notes plus more than 15.8 million new shares. Website StockNews.com also downgraded the stock from hold to sell.
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
– Research published in European Urology Oncology shows restrictive genetic testing criteria miss a significant number of prostate cancer patients with potentially actionable inherited variants – – Offering germline testing to all prostate cancer patients could improve access to critical...
Down 96%, Is Invitae Stock a Buy?
The innovative medical services company is making adjustments to improve the bottom line.
Invitae Corporation (NVTA) Q2 2023 Earnings Call Transcript
Invitae Corporation (NYSE:NVTA ) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President and CEO Conference Call Participants Dan Brennan - Cowen Madison Pasterchick...
Best Penny Stocks To Buy? 6 To Watch Before Next Week
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
SAN FRANCISCO , July 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast...
Down 97%, Is It Finally Time to Buy Invitae Stock?
Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beaten-down Invitae could provide huge returns if it can regain a fraction of its former market cap.
Invitae (NVTA) Upgraded to Buy: Here's Why
Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down 98% Is This Cathie Wood Stock a Screaming Buy?
Popular investment manager Cathie Wood is known for investing in innovative growth stocks.
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Emergent BioSolutions just got a nod from regulators for over-the-counter use of a product to fight opioid overdose. Invitae is making progress on a plan to reach positive cash flow.
Source: https://incomestatements.info
Category: Stock Reports